http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7560531-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8979f668f006ff308baf5a67e4889779 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate | 2004-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91d32737ed330f157c46ac0536fcad51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d08aa47040e42ff44a8df742690e06a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d779932700b4929a09cd22adb10ec03 |
| publicationDate | 2009-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7560531-B2 |
| titleOfInvention | Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers |
| abstract | This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln10I antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal. |
| priorityDate | 2003-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 427.